Нарушения липидного обмена: диагностика и лечение

1. Нарушения липидного обмена. Клинические рекомендации. 2025. URL: https://cr.minzdrav.gov.ru/view-cr/752_1

2. Болезни сердца по Браунвальду: руководство по сердечно-сосудистой медицине. под ред. П. Либби и др.; пер. с англ. под общ. ред. Р.Г. Оганова. В 4-х т. Том 1. М.: Логосфера, 2012. 596 с.: ил.

3. Liu J., et al. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids in Health and Disease. 2013;12(1):1–11.

4. Amarenco P., Labreuche J.. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurology. 2009;8(5):453–463.

5. Ershova A., Balakhonova T., Meshkov A., et al. Carotid and femoral artery plaques as predictors of cardiovascular and all-cause mortality in the middle-aged general population. Atherosclerosis Supplements. 2022;355:e43–e44. doi: 10.1016/j.atherosclerosis.2022.06.212.

6. Ежов М.В., Бажан С.С., Ершова А.И. и др. Клинические рекомендации по семейной гиперхолестеринемии. Атеросклероз. 2019;15(1):58–98.

7. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–2454.

8. Holewijn S., et al. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. J Int Med. 2010;268(6):567–577.

9. Blonde L., Umpierrez G.E., Reddy S.S., et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022 Oct;28(10):923–1049. doi: 10.1016/j.eprac.2022.08.002.

10. Pletcher M.J., et al. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Int Med. 2004;164(12):1285–1292.

11. Балахонова Т.В., Ершова А.И., Ежов М.В. и др. Фокусированное ультразвуковое исследование сосудов. Консенсус российских экспертов. Кардиоваскулярная терапия и профилактика. 2022;21(7):3333. doi: 10.15829/1728-8800-2022-3333.

12. Eckel R.H., Jakicic J.M., Ard J.D., et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. Circulation. 2013;129(25 suppl 2):S76–S99. doi: 10.1161/01.cir.0000437740.48606.d1

13. Estruch R., Ros E., Salas-Salvado J., et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. doi: 10.1056/NEJMoa1800389.

14. Oscarsson J., Önnerhag K., Riserus U., et al. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. J Clin Lipidol. 2018 Nov-Dec;12(6):1390–1403.e4. doi: 10.1016/j.jacl.2018.08.003.

15. Lu Z., Kou W., Du B., et al. Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction. Am J Cardiol. 2008;101(12):1689–93. doi: 10.1016/j.amjcard.2008.02.056.

16. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database System Rev. 2013. doi: 10.1002/14651858.cd004816.pub5.

17. Vallejo-Vaz A.J., et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. Circulation. 2018;138(8):770–781.

18. Bohula E.A., Wiviott S.D., Giugliano R.P., et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017;136:2440–2450. doi: 10.1161/CIRCULATIONAHA.117.029095.

19. Schreml J., Gouni-Berthold I. Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance. Current medicinal chemistry. 2018;25(13):1538–1548.

20. Klebs S., Lecocq J., Mann С., et al. Characterization of Inclisiran Use in Real World: Prescription Data from Germany. J Clin Lipidol. 2022;16(3):Suppl e73. doi: 10.1016/j.jacl.2022.05.060.

21. Rohit D., Shankar J. Comparative Study of Atorvastatin and Rosuvastatin in Combination with Fenofibrate in mixed Hyperlipidemia. Int J Pharmacol Clin Sci. 2016;5(1):25–31.